Clinical trial NCT06031311: Pulmonaryhypertension in Copd at Different Levels of Smoking
Official title: Clinical Characteristics and Predictors of Pulmonary Hypertension in COPD at Different Levels of Smoking
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Pulmonary Hypertension
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2023-09-11
Enrollment: 138
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Full clinical history including:\[demographic data and clinical symptoms including cough with expectoration ,dyspnea,chest wheeze,...etc\] 2.Full clinical examination. 3.laboratory investigations: Complete blood picture , kidney function test, liver function test,coagulation profile 4.Arterial blood gases \[Pao2, Paco2,Sao2,Hco3, P(A_a)o2 \] 5.PFTS:will be performed and classified into: Post bronchodilator FEV1/FVC \<0.7

GOLD 1 - mild: FEV1 ≥80% predicted. GOLD 2 - moderate: 50% ≤ FEV1 \<80% predicted. GOLD 3 - severe: 30% ≤ FEV1 \<50% predicted. GOLD 4 - very severe: FEV1 \<30% predicted \[5\] 6.Echocardiography:is non invasive and easily accessible tool in the diagnosis of any patient with suspected PH. ePASP is estimated by calculating Doppler estimated trans tricuspid gradient (TR gradient= 4 x (TR velocity)2) and adding estimated right atrial pressure to it based on the size of the inferior vena cava and collapsibility.\[6\]

Brief summary: To identify Predictors of pulmonary hypertension in COPD patients and its relation to different levels of smoking

Detailed description: COPD is a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, expectoration and/or exacerbations) due to abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction.It is also the most common cause of deaths in patients with chronic respiratory disease, the fatality rate in USA is 0.41%.Pulmonary Hypertension is the most common serious complication in COPD patients ; which occurs in up to 30% of patients and increases the mortality rate.Smoking is the leading cause of chronic obstructive pulmonary disease (COPD) Smoking is also a trigger for COPD flare-ups.Smoking damages the air sacs, airways, and the lining of your lungs. Injured lungs have trouble moving enough air in and out, so it's hard to breathe

Eligibility criteria: Inclusion Criteria:

* 1.All patients admitted to chest department or presented to our outpatient clinic with clinical and functional diagnosis of COPD among both sexes will be included 2.Age \>18 years Old

Exclusion Criteria:

* 1.Patients under 18 years old. 2.pregnant patients. 3.patients with history hypertension or valvular diseases 4.Cardiomyopathic patient 5.Patients with concomitant obstructive sleep apnea 6.Patients with collagen vascular disease 7.Patients with thrombo-embolic disease 8. Patients with any chronic chest disease other than COPD

Primary outcomes:
measure: Predictors of pulmonary hypertension in COPD patients
timeFrame: 1 year
Secondary outcomes:
measure: Relationship between different levels of smoking and predictors of degree of pulmonary hypertension
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
References: